This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Advancing PET Imaging for the Assessment of Recurrent Brain Metastases

Advancing PET Imaging for the Assessment of Recurrent Brain Metastases

11:00 am - Wednesday 22nd July 2026

Addressing the clinical challenge of differentiating tumor recurrence from treatment-related changes following radiotherapy
Presenting the clinical development of 18F-RAD101 as a novel PET imaging agent designed to improve diagnostic accuracy
Exploring the potential impact of PET imaging on patient management and clinical decision making in neuro-oncology

Speakers:

Dimitris Voliotis

Chief Medical Officer

RadioPharm Theranostics